Single-center, Double-blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs AC 082 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions; First in man
- Sponsors Actelion Pharmaceuticals
- 08 Jun 2017 Status changed from recruiting to completed.
- 18 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
- 18 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.